Company / PP&E (Net)
ADMA Biologics, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$65.1M
FY2025
5-year range
$50.9M / $65.1M
FY2021-FY2025
Trend
+18.9%
vs FY2024
Sector context
#56 of 193
Health Care
What the data says
At $65M, ADMA Biologics, Inc.'s pp&e (net) ranks #56 of 193 in the Health Care sector. PP&E (Net) has fluctuated over the past 10 years, ranging from $2M in FY2016 to $65M in FY2025.
Based on SEC 10-K filings.
$65M in FY2025 with a 5-year CAGR of +9.4%.
Improved from $54M to $65M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +3.7%
- 5-Year CAGR
- +9.4%
- 10-Year CAGR
- -
Sector benchmark
#56 of 193 in Health CareTop 29% of 193This company $65.1M Sector average $777.6M
▼
-91.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.4%, indicating consistent growth.
- In FY2025, pp&e (net) increased 18.9% year-over-year.
- Ranks #56 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $65.1M | +18.9% |
| FY2024 | $54.7M | +1.6% |
| FY2023 | $53.8M | -7.6% |
| FY2022 | $58.3M | +14.4% |
| FY2021 | $50.9M | +22.5% |
| FY2020 | $41.6M | +31.0% |
| FY2019 | $31.7M | +5.4% |
| FY2018 | $30.1M | -1.2% |
| FY2017 | $30.5M | +1422.7% |
| FY2016 | $2.0M | -16.5% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026